Dawson M I, Chao W R, Hobbs P D, Zhang X K
Retinoid Program, SRI International, Menlo Park, CA 94025, USA.
Cancer Lett. 1998 Nov 13;133(1):1-8. doi: 10.1016/s0304-3835(98)00147-5.
Breast cancer cell growth inhibition was not synergistically enhanced by trans-retinoic acid (RA) or 9-cis-RA plus 1alpha,25-(dihydroxy)vitamin D3 (DHVD). The retinoid/DHVD combinations did lower their 50% effective concentrations for inhibiting retinoid-sensitive MCF-7, but not retinoid-refractory BT-20, breast cancer cell growth. In contrast, the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) and its analog SR11389 inhibited the growth of both cell lines. Unlike RA, 9-cis-RA and DHVD, AHPN and SR11389 also potently inhibited human umbilical vascular endothelial cell growth. These results on AHPN and SR11389 suggest that angiogenesis of tumor microvasculature should also be an effective therapeutic target for this new compound class.
全反式维甲酸(RA)或9-顺式维甲酸加1α,25-(二羟基)维生素D3(DHVD)并未协同增强对乳腺癌细胞生长的抑制作用。维甲酸/DHVD组合确实降低了它们抑制对维甲酸敏感的MCF-7乳腺癌细胞生长的50%有效浓度,但对维甲酸难治的BT-20乳腺癌细胞生长无效。相比之下,合成维甲酸6-[3-(1-金刚烷基)-4-羟基苯基]-2-萘甲酸(AHPN)及其类似物SR11389抑制了这两种细胞系的生长。与RA、9-顺式维甲酸和DHVD不同,AHPN和SR11389还能有效抑制人脐血管内皮细胞的生长。这些关于AHPN和SR11389的结果表明,肿瘤微血管的血管生成也应该是这类新化合物的一个有效治疗靶点。